Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Taro Pharmaceutical Indus Q2 2023 Adj.EPS $0.38 Beats $0.18 Estimate, Sales $148.20M Miss $161.14M Estimate

Author: Benzinga Newsdesk | October 26, 2023 05:11pm
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.18 by 111.11 percent. This is a 42.42 percent decrease over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $148.20 million which missed the analyst consensus estimate of $161.14 million by 8.03 percent. This is a 13.57 percent increase over sales of $130.50 million the same period last year.

Posted In: TARO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist